Astrocytes and microglia-targeted Danshensu liposomes enhance the therapeutic effects on cerebral ischemia-reperfusion injury
Journal of Controlled Release · 2023-12 · 364 · 473-489
DOI: 10.1016/j.jconrel.2023.11.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-12. Verfasst von Min Bai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. Hauptthemen laut MEDLINE: Brain Ischemia, Reperfusion Injury. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cerebral ischemia-reperfusion injury (CI/RI) is the main cause of disability and death in stroke without satisfactory therapeutic effect. Inflammation mediated by activation of astrocytes and microglia is the main pathological mechanism of CI/RI. Danshensu (DSS) has been shown to exert anti-inflammatory effects against brain injury. However, limited by its poor cellular permeability and low bioavailability, it is still needed the new DSS preparations with the ability to cross the blood-brain barrier (BBB) and target inflammatory glial cells. In this study, we developed phosphatidylserine (PS) and transferrin (TF) modified liposomes carrying DSS (TF/PS/DSS-LPs) to improve the therapeutic efficacy against ischemic stroke. First, TF molecules targeted transferrin receptor (TfR) that is overexpressed in the BBB. Following the liposomes enter the brain, PS modification allowed the liposomes to target and bind to the overexpressed phosphatidylserine-specific receptors (PSRs) on the surface of astrocytes and microglia. Furthermore, it enhanced the uptake of TF/PS/DSS-LPs by astrocytes and microglia, while polarizing astrocytes from A1 to A2 and microglia from M1 to M2, reducing neuronal inflammation, and ultimately ameliorating cerebral ischemic injury. Thus, TF/PS/DSS-LPs could potentially serve as a promising strategy for the CI/RI treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China; Department of Pharmacology, Shaanxi University of Traditional Chinese medicine, Xianyang 712046, China.
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. Electronic address: adwen-2004@hotmail.com.
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. Electronic address: wangjingwen8021@163.com.
- Department of Pharmaceutics, School of Pharmacy, Air Force Medical University, Xi'an 710032, China. Electronic address: yaojixue@fmmu.edu.cn.
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. Electronic address: dingyi.007@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Bai, M., Cui, N., Liao, Y., Guo, C., Li, L., Yin, Y., Wen, A., Wang, J., Ye, W., & Ding, Y. (2023). Astrocytes and microglia-targeted Danshensu liposomes enhance the therapeutic effects on cerebral ischemia-reperfusion injury. Journal of Controlled Release, 364, 473-489. https://doi.org/10.1016/j.jconrel.2023.11.002
Vancouver
Bai M, Cui N, Liao Y, Guo C, Li L, Yin Y, et al. Astrocytes and microglia-targeted Danshensu liposomes enhance the therapeutic effects on cerebral ischemia-reperfusion injury. Journal of Controlled Release. 2023;364:473-489. doi:10.1016/j.jconrel.2023.11.002
BibTeX
@article{Bai2023,
author = {Bai, Min and Cui, Na and Liao, Yucheng and Guo, Chao and Li, Liang and Yin, Ying and Wen, Aidong and Wang, Jingwen and Ye, Weiliang and Ding, Yi},
title = {Astrocytes and microglia-targeted Danshensu liposomes enhance the therapeutic effects on cerebral ischemia-reperfusion injury},
journal = {Journal of Controlled Release},
year = {2023},
volume = {364},
pages = {473--489},
doi = {10.1016/j.jconrel.2023.11.002}
}
EUVIMED